JP2003522112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522112A5 JP2003522112A5 JP2000578009A JP2000578009A JP2003522112A5 JP 2003522112 A5 JP2003522112 A5 JP 2003522112A5 JP 2000578009 A JP2000578009 A JP 2000578009A JP 2000578009 A JP2000578009 A JP 2000578009A JP 2003522112 A5 JP2003522112 A5 JP 2003522112A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- anxiety
- disorder
- tofisopam
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019901 Anxiety disease Diseases 0.000 description 40
- 239000008194 pharmaceutical composition Substances 0.000 description 40
- 238000000034 method Methods 0.000 description 25
- RUJBDQSFYCKFAA-HNNXBMFYSA-N (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1([C@H](C(=NN=2)C)CC)=CC(OC)=C(OC)C=C1C=2C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-HNNXBMFYSA-N 0.000 description 14
- 230000036506 anxiety Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229960002501 tofisopam Drugs 0.000 description 6
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- -1 (±) -venlafaxine Chemical compound 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 2
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10580398P | 1998-10-27 | 1998-10-27 | |
| US60/105,803 | 1998-10-27 | ||
| PCT/US1999/025040 WO2000024400A1 (en) | 1998-10-27 | 1999-10-27 | Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007136619A Division JP2007211028A (ja) | 1998-10-27 | 2007-05-23 | 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003522112A JP2003522112A (ja) | 2003-07-22 |
| JP2003522112A5 true JP2003522112A5 (enExample) | 2007-02-01 |
Family
ID=22307874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000578009A Pending JP2003522112A (ja) | 1998-10-27 | 1999-10-27 | 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物 |
| JP2007136619A Withdrawn JP2007211028A (ja) | 1998-10-27 | 2007-05-23 | 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007136619A Withdrawn JP2007211028A (ja) | 1998-10-27 | 2007-05-23 | 不安障害の処置および予防への光学的に純粋な（ｒ）−トフィソパムの使用およびその組成物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1124556B1 (enExample) |
| JP (2) | JP2003522112A (enExample) |
| AT (1) | ATE269705T1 (enExample) |
| AU (1) | AU1451900A (enExample) |
| BR (1) | BR9914899A (enExample) |
| CA (1) | CA2348281A1 (enExample) |
| DE (1) | DE69918322T2 (enExample) |
| DK (1) | DK1124556T3 (enExample) |
| ES (1) | ES2224751T3 (enExample) |
| GB (1) | GB2367748A (enExample) |
| HK (2) | HK1040908B (enExample) |
| IL (2) | IL142803A0 (enExample) |
| NZ (1) | NZ511744A (enExample) |
| PT (1) | PT1124556E (enExample) |
| WO (1) | WO2000024400A1 (enExample) |
| ZA (1) | ZA200103376B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649607B2 (en) | 2001-05-18 | 2003-11-18 | Vela Pharmaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
| CA2483093A1 (en) * | 2002-04-24 | 2003-11-06 | Cypress Bioscience, Inc. | Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain |
| US6864251B2 (en) | 2002-12-03 | 2005-03-08 | Vela Pharmaceuticals, Inc. | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines |
| JP2006514084A (ja) * | 2002-12-03 | 2006-04-27 | ヴェラ ファーマスーティカルズ インコーポレイテッド | １−（３−ヒドロキシ−４−メトキシフェニル）−４−メチル−５−エチル−７，８−ジメトキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途 |
| US7022700B2 (en) | 2002-12-03 | 2006-04-04 | Vela Pharmaceuticals, Inc. | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines |
| AU2003293405A1 (en) | 2002-12-03 | 2004-06-23 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
| US6638928B1 (en) * | 2002-12-03 | 2003-10-28 | Vela Pharmaceuticals, Inc. | Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines |
| CA2525273C (en) * | 2003-05-16 | 2012-04-17 | Vela Pharmaceuticals, Inc. | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine |
| EP1689408A4 (en) * | 2003-12-03 | 2010-03-03 | Vela Acquisition Corp | TREATMENT OF INFLAMMATORY DISORDERS OF EPITHELIUM USING LOW DOSE 2,3-BENZODIAZEPINES |
| FR2870539B1 (fr) * | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| US7541355B2 (en) | 2005-05-23 | 2009-06-02 | Vela Acquisition Corporation | Conversion process for 2,3-benzodiazepine enantiomers |
| CN102836162A (zh) * | 2012-04-10 | 2012-12-26 | 珠海亿邦制药股份有限公司 | 一种以托非索泮为活性成分的口服固体制剂及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK118660B (da) * | 1966-12-09 | 1970-09-21 | Egyt Gyogyszervegyeszeti Gyar | Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid. |
| ZA712798B (en) * | 1970-11-06 | 1972-02-23 | Egyt Gyogyszervegyeszeti Gyar | New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same |
| HU178516B (en) * | 1978-05-05 | 1982-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere |
| HU209530B (en) * | 1988-08-31 | 1994-07-28 | Magnezitipari Muevek Rt | Process for manufacturing of cromit-like, fire resistant materials |
-
1999
- 1999-10-27 CA CA002348281A patent/CA2348281A1/en not_active Abandoned
- 1999-10-27 JP JP2000578009A patent/JP2003522112A/ja active Pending
- 1999-10-27 DE DE69918322T patent/DE69918322T2/de not_active Expired - Fee Related
- 1999-10-27 GB GB0111739A patent/GB2367748A/en not_active Withdrawn
- 1999-10-27 HK HK02100988.2A patent/HK1040908B/en not_active IP Right Cessation
- 1999-10-27 ES ES99970920T patent/ES2224751T3/es not_active Expired - Lifetime
- 1999-10-27 EP EP99970920A patent/EP1124556B1/en not_active Expired - Lifetime
- 1999-10-27 NZ NZ511744A patent/NZ511744A/en unknown
- 1999-10-27 AU AU14519/00A patent/AU1451900A/en not_active Abandoned
- 1999-10-27 HK HK02106802.3A patent/HK1046500A1/zh unknown
- 1999-10-27 IL IL14280399A patent/IL142803A0/xx active IP Right Grant
- 1999-10-27 AT AT99970920T patent/ATE269705T1/de not_active IP Right Cessation
- 1999-10-27 PT PT99970920T patent/PT1124556E/pt unknown
- 1999-10-27 WO PCT/US1999/025040 patent/WO2000024400A1/en not_active Ceased
- 1999-10-27 DK DK99970920T patent/DK1124556T3/da active
- 1999-10-27 BR BR9914899-4A patent/BR9914899A/pt not_active Application Discontinuation
-
2001
- 2001-04-25 IL IL142803A patent/IL142803A/en not_active IP Right Cessation
- 2001-04-25 ZA ZA200103376A patent/ZA200103376B/en unknown
-
2007
- 2007-05-23 JP JP2007136619A patent/JP2007211028A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2095062C1 (ru) | Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены | |
| US5776969A (en) | Treatment of sleep disorders | |
| AU762128B2 (en) | Agents with an antidepressive effect | |
| FI116659B (fi) | Yhdisteiden käyttö valmistettaessa lääkettä multippeliskleroosin (MS) ja muiden myeliinikatotilojen hoitoon | |
| CA2301899C (en) | Agent with an antidepressant activity | |
| AU761510B2 (en) | Combination therapy for treatment of refractory depression | |
| JP2003522112A5 (enExample) | ||
| TW200831097A (en) | Treatment of anxiety with eszopiclone | |
| CA2592631A1 (en) | Compositions and methods to treat recurrent medical conditions | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| CA2245871A1 (en) | Treatment of sleep disorders | |
| CY1653A (en) | Pharmaceutical compositions with analgesic properties and the preparation and use thereof | |
| US20190076409A1 (en) | Use of gaboxadol in the treatment of narcolepsy | |
| WO1997006792A1 (en) | Potentiation of serotonin response | |
| KR20040030788A (ko) | 요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체 | |
| CN103041389A (zh) | 使用毒蕈碱型受体m1拮抗剂治疗心理学病况 | |
| ES2211205T3 (es) | Composiciones farmaceuticas que contienen olanzapina-n-oxido. | |
| WO1992018005A1 (en) | Method of treating trichotillomania and onychophagia | |
| NL8002041A (nl) | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. | |
| CN1197569C (zh) | 神经病症的新疗法 | |
| KR20010099648A (ko) | 신규 조성물 | |
| CN101472571A (zh) | 使用毒蕈碱型受体m1拮抗剂治疗心理学病况 | |
| CA2338326A1 (en) | Use of moclobemide and metabolites for treating and preventing substance abuse | |
| EP1578428A2 (en) | Treating alcohol and or substance abuse by antagonizing alpha a2 drenergic receptors with weak dopamine blocking |